Monthly Archives: July 2014

USPTO TRIPs over Myriad-Mayo guidance

Timothy W. Roberts, Chartered Patent Attorney; MA (Oxon); LL.D (honoris causa, Sheffield University) Paul G. Cole,  Chartered Patent Attorney;  MA (Oxon); LLM, NottinghamTrent; Visiting Professor, Bournemouth University The above UK-based European Practitioners have today filed comments at the USPTO arguing … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , | 1 Comment

FDA Accepts First Biosimilar Application for Review

In an important step forward for the introduction of “generic biological,” the FDA announced that it has accepted Sandoz’s application to market a generic version of Amgen’s Neupogen®, which stimulates white blood cell production. As you may recall, about two years … Continue reading

Posted in FDA | Tagged , , , , , , , , , , , , | Leave a comment

Q. Todd Dickinson Resigns as Executive Director of AIPLA

After six years as AIPLA Executive Director, Q. Todd Dickinson has announced that he will step down. While he was an effective leader at AIPLA, Todd (the “Q” doesn’t stand for anything) made his mark as the first effective Director … Continue reading

Posted in People | Tagged , , , | Leave a comment

Myriad Guidance Comments

The USPTO is now publishing comments http://www.uspto.gov/patents/law/comments/myriad-mayo_guidance_comments.jsp  

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , | 1 Comment